Quarterly ResultAug 13, 2026, 04:19 PM
Co-Diagnostics Q2 Net Loss $6.28M; Going Concern Doubt
AI Summary
Co-Diagnostics, Inc. reported a net loss of $6.28 million for the second quarter of 2026 and $15.42 million for the first half of 2026. The company's cash and cash equivalents significantly decreased to $3.65 million by June 30, 2026, from $11.88 million at year-end 2025. Management has concluded that substantial doubt exists about the company's ability to continue as a going concern, dependent on obtaining additional financing and achieving operational efficiencies.
Key Highlights
- Net loss for Q2 2026 was $(6.28) million, compared to $(7.73) million in Q2 2025.
- Net loss for H1 2026 was $(15.42) million, compared to $(15.26) million in H1 2025.
- Cash and cash equivalents decreased to $3.65 million as of June 30, 2026, from $11.88 million at year-end 2025.
- Management concluded substantial doubt exists about the company's ability to continue as a going concern.
- Net cash used in operating activities for H1 2026 was $(15.00) million.
- Product revenue for Q2 2026 was $166,131, up from $162,910 in Q2 2025.
- Raised $4.59 million net from at-the-market offering in H1 2026.
- Implemented a 1-for-30 reverse stock split on January 1, 2026.
Price Impact
More from CODX